Fiche centre
Research Site
Linz — Austria
Essais liés4clinical trials
VilleLinzlocalisation
PaysAustrialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07691970
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Acalabrutinib (ACP-196) | Cancer | Phase 3 | NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Myopathies | Phase 3 | NCT07691970 | ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | RECRUITING |
| ASTER — A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice | Lupus | À vérifier | NCT05637112 | ASTER — A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice | ACTIVE_NOT_RECRUITING |
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |